

# Novo Nordisk in Iceland Investing beyond medicine

Driving change to defeat diabetes  
and other serious chronic diseases  
sustainably



# Driving change through innovation

Novo Nordisk is a global healthcare company founded and headquartered in Denmark

Founded in 1923, Novo Nordisk has been pioneering life-saving treatments and medicines to drive change to defeat diabetes and other serious chronic diseases and improve people's lives for almost a century. In 2021, Novo Nordisk reached 34.6 million people with its diabetes products globally.<sup>1</sup> In Iceland, an estimated 20,000 people live with diabetes<sup>2</sup>, of whom 30% use Novo Nordisk products.

Novo Nordisk has had a presence in Iceland for nearly 48 years, working to ensure the availability of much-needed and innovative treatments. At the same time as investing in patients, Novo Nordisk has invested in the education and training of healthcare professionals. Novo Nordisk also participates in critical discussions on relevant disease areas and contributes to the broader society in Iceland through substantive grants to scientific, social and humanitarian causes.

## Novo Nordisk worldwide

### Global access to products

**168 countries** with marketed products



### Countries where Novo Nordisk operates

**80 countries** with affiliates



### Products and innovation

**5 countries** with research and development facilities



## Iceland at a glance

### Company presence

**1975** Novo Nordisk began operating in Iceland



### Reaching people with diabetes

**Almost 7,000 people** with diabetes in Iceland reached with Novo Nordisk diabetes care in 2021

### Funding provided

**ISK 75 million** in grants provided by the Novo Nordisk Foundation in Iceland since 2016


# Creating value for society, globally


Novo Nordisk's key contribution is discovering and developing innovative biological medicines and making them accessible to patients worldwide. The aim is to lead in all disease areas in which the company is active.

 **Diabetes care**

 **Obesity care**

 **Rare diseases**

 **Other serious chronic disease**  
such as NASH, cardiovascular disease and Alzheimer disease



\* Number of unique HCPs educated by independent medical education activities supported through educational grants

\*\*Currency converted from Danish Krone, June 2022

# Diabetes and obesity, a public health challenge

The rising incidence of diabetes and obesity are serious challenges facing society worldwide and in Iceland

For people living with obesity or diabetes, the mental and physical toll can be enormous. The societal costs and the economic burden of managing the conditions have already reached an unsustainable level and are increasing.

Given the devastating human and economic cost of diabetes and its complications on individuals, their families, communities, and society, this growth is unsustainable.

***Novo Nordisk aims to raise the innovation bar for diabetes treatment and develop a leading portfolio of superior treatment solutions for obesity.***

Recent estimates highlighted on the burden of diabetes and obesity vary by year.

\*Converted from US dollars, June 2022.



**39.7% of adults**  
in Iceland are overweight<sup>3</sup>

**22.3% of adults**  
In Iceland are living with obesity<sup>3</sup>



**ISK 21.8 billion\*** was the estimated total diabetes-related health expenditure in Iceland in 2021

**13.4% of children** aged 5-7 years in Iceland are overweight<sup>4</sup>



**20,000 adults** in Iceland are estimated to have diabetes<sup>2</sup>

**4.4%** of children aged 5-7 years are living with obesity<sup>4</sup>

**100 children and adolescents** aged 0-19 years in Iceland are estimated to have type 1 diabetes<sup>2</sup>



# Novo Nordisk in Iceland

Investing in science, people, society  
and the future

Novo Nordisk has been operating in Iceland since **1975** and is an active investor in people, research, and the country. The Novo Nordisk Foundation has provided grants in Iceland for ISK 75 million since 2016. Novo Nordisk employs four people in Iceland.

Novo Nordisk is an active participant at NORDCOAG Symposium 2022 (the 55th Nordic Coagulation meeting) in August/September in Reykjavik. Novo Nordisk also participated in SSSD congress held in May 2022 in Reykjavik.



## Patients and Healthcare professionals

**+800**

HCPs received training through Novo Nordisk activities or participated in events in Iceland in 2021

## HCP training

covering diabetes type 1 and type 2 screening, diagnosis, treatment and follow-up care is offered in Iceland

## Specialist training

of diabetes staff is offered at the National University Hospital of Iceland



## Patients and medicines

**67%**

of the insulin used in Iceland is produced by Novo Nordisk



**30%**

of people with diabetes in Iceland use Novo Nordisk diabetes products





# Environmental responsibility

Novo Nordisk integrates environmental considerations into everything it does

Novo Nordisk is taking bold, broad, company-wide approaches to solve environmental issues – with the ultimate aspiration to have zero environmental impact.

By 2045, the company has committed to net zero emissions across its global value chain, a significant milestone of which will be achieving the target of zero CO<sub>2</sub> emissions from operations and transport by 2030.



This chair used to be 120 insulin pens

## Building a greener, healthier future in Iceland



### Reduction in air travel

Flights will be reduced year on year to achieve zero CO<sub>2</sub> emissions by 2030.



### Renewable power

In 2020, Novo Nordisk achieved its goal of using 100% renewable electricity across our global production. All offices will run on renewable power by 2030 at the latest.



### Going electric

Novo Nordisk is targeting zero CO<sub>2</sub> emissions from company cars in 2030. The ambition is to reach 100% all-electric or plug-in hybrid by 2025.



### Innovating to zero waste

Novo Nordisk collects used insulin pens in several countries, e.g. Denmark, UK and Brazil, to recycle plastic, metal and glass from scrapped pens into other products, e.g. chairs and lamps.

NOVO  
NORDISK  
FONDEN

## Focused on shared value creation

The Novo Nordisk Foundation invests in projects which benefit society. The figures below show the financial backing totalling ISK 164 billion to support progress in science, learning and humanitarian causes in 2021.



**ISK 72.4bn** Biomedical and health science research and applications



**ISK 22.45bn** Life science research and industrial applications promoting



**ISK 19.4bn** Innovation



**ISK 16.5bn** Education and outreach



**ISK 16.3bn** Natural and technical science and interdisciplinary research



**ISK 12.9bn** Social, humanitarian and development aid



**ISK 3.8bn** Clinical sciences

# Committed to global action

Novo Nordisk is committed to driving change in diabetes and other serious chronic diseases. The company plays a significant role as a global catalyst in driving change to defeat societal challenges like diabetes and obesity.

novonordiskfonden

Now the **world's largest foundation**, it was created in 1927 to support scientific, social and humanitarian causes<sup>5</sup>

Since 2016, grants of **ISK 484 billion** have been dispersed to society<sup>5</sup>



WORLD **DIABETES** FOUNDATION

**Established by Novo Nordisk in 2002** as an independent trust dedicated to the prevention and treatment of diabetes in developing countries<sup>6</sup>

Novo Nordisk's commitment to the Foundation is more than **ISK 4.8 billion** covering the period up to 2024<sup>7</sup>

Driving change | in diabetes

**3 USD per vial** ceiling price of human insulin in 76 low- and middle-income countries<sup>7</sup>

More than **30,000 children with type 1 diabetes** living in low resource settings receive care and insulin through the Changing Diabetes® in Children programme<sup>7</sup>



novonordisk  
haemophilia foundation

A trusted partner to the global haemophilia community since its creation as a non-profit, grant-making foundation in 2005<sup>8</sup>

**29,700 people with haemophilia** have been diagnosed or retested through programmes supported by the Foundation<sup>8</sup>

## Get in touch

### Novo Nordisk Denmark & Iceland

Phone: +45 45880800 (Denmark)

Phone: +354-8247021

(Iceland) Mail:

dyrs@novonordisk.com

## References

1. Novo Nordisk. *Novo Nordisk 2021 Annual Report*. 2022:103. Accessed April 2022. [https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual\\_report/2022/novonordisk-annual-report-2021.pdf](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2022/novonordisk-annual-report-2021.pdf)
2. International Diabetes Federation. *IDF Diabetes Atlas 10th ed*. Accessed November, 2021. <https://diabetesatlas.org>
3. Eurostat. Body mass index (BMI) by sex, age and income quintile. Accessed May, 2022. [https://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth\\_ehis\\_bm1i&lang=en](https://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_ehis_bm1i&lang=en)
4. World Health Organization. Obesity and overweight. Updated June 2021. Accessed February, 2022. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
5. Novo Nordisk Foundation. Our vision is to improve people's health and the sustainability of society and the planet. <https://novonordiskfonden.dk/en/>
6. World Diabetes Foundation (WDF). 20 years of improving live together. <https://www.worlddiabetesfoundation.org>
7. Novo Nordisk. Our position on access to diabetes care. Accessed June, 2022. <https://www.novonordisk.com/sustainable-business/access-and-affordability/access-to-diabetes-care-position.html>
8. Novo Nordisk Haemophilia Foundation. Striving for better access to care. <https://nnhf.org/about-us/>